Hyperfine stock reports record Q3 revenue, narrower loss

Published on 11/12/2026 at 02:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Hyperfine stock follows a record quarter as revenue and gross margin reached new highs. Management kept its 2026 outlook unchanged.

Record quarter improves operating trend

Hyperfine sold more Swoop systems and expanded its international rollout during the third quarter.
Management maintained its 2026 revenue and net cash burn outlook after the quarterly results.
The company expects to submit a contrast-imaging application to the FDA by the end of 2026.

Hyperfine stock, HYPR, Swoop system, portable MRI, third-quarter results, medical technology, Illustration mit AI erstellt.

Hyperfine reported record third-quarter results on Monday, November 9, 2026, with revenue growth, higher gross profit and a narrower operating loss. The company also said its quarterly revenue exceeded net cash burn for the first time. The results were published by Financial Times.

Revenue growth reaches new high

Revenue for the quarter ended September 30 rose to 6.0 million US dollars from 3.4 million US dollars a year earlier, an increase of 73 percent. Hyperfine sold 14 commercial Swoop systems, compared with eight in the prior-year quarter.

Gross profit climbed to 3.4 million US dollars from 1.8 million US dollars, while gross margin reached 57 percent versus 54 percent a year earlier. The operating loss narrowed to 7.3 million US dollars from 8.9 million US dollars. Net loss fell to 6.0 million US dollars, or 0.06 US dollars per share, from 11.0 million US dollars, or 0.14 US dollars per share.

Cash burn and outlook

Net cash burn was 5.6 million US dollars, down from 7.9 million US dollars in the second quarter and 5.9 million US dollars a year earlier. Hyperfine held 37.9 million US dollars in cash and cash equivalents at September 30. The company said it generated no financing proceeds during the quarter.

Management maintained its full-year 2026 revenue outlook of 20 million to 22 million US dollars and its net cash burn outlook of 26 million to 28 million US dollars. The company expects to submit an application to the US Food and Drug Administration for contrast imaging by the end of 2026.

Business model and market position

Hyperfine develops portable, ultra-low-field magnetic resonance imaging systems for brain imaging at multiple points of professional care. Its Swoop system is FDA-cleared and can be used at hospital bedsides, in neurology offices and in other care settings, while Optive AI software supports image acquisition and interpretation workflows. The company is headquartered in the United States and focuses on expanding access to brain imaging through a portable system rather than a conventional fixed MRI installation.